Influence of CYP2C9 and CYP2D6 Polymorphisms on the Pharmacokinetics of Nateglinide in Genotyped Healthy Volunteers

By Kirchheiner J.  

Clinical Pharmacokinetics, Vol. 43, Iss. 4, 2004-01 ,pp. : 267-278

Adis International

Access to resources Recommend Favorite

Effect of a selective CYP2C9 inhibitor on the pharmacokinetics of nateglinide in healthy subjects

By Sabia Helene   Sunkara Gangadhar   Ligueros-Saylan Monica   Wang Yibin   Smith Harold   McLeod James   Prasad Pratapa  

European Journal of Clinical Pharmacology, Vol. 60, Iss. 6, 2004-09 ,pp. : 407-412

Springer Publishing Company

Access to resources Recommend Favorite

Effect of Genetic Polymorphisms in Cytochrome P450 (CYP) 2C9 and CYP2C8 on the Pharmacokinetics of Oral Antidiabetic Drugs: Clinical Relevance

By Kirchheiner Julia   Roots Ivar   Goldammer Mark   Rosenkranz Bernd  

Clinical Pharmacokinetics, Vol. 44, Iss. 12, 2005-01 ,pp. : 1209-1225

Adis International

Access to resources Recommend Favorite

Warfarin: CYP2C9 polymorphisms increase risk of bleeding events

By  

Inpharma, Vol. 1, Iss. 1333, 2002-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite

Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with Type 2 diabetes mellitus

By Swen Jesse J   Wessels Judith AM   Krabben Annemarie   Assendelft Willem JJ   Guchelaar Henk-Jan  

Pharmacogenomics, Vol. 11, Iss. 11, 2010-11 ,pp. : 1517-1523

Future Medicine

Access to resources Recommend Favorite